Tex. / Cincinnati / Gliwice / Rochester / Siena / Seattle / Houston / Rockville / Bern / Boston / New York / Pisa / Ferrara / Pittsburgh / Erlangen / Milan / Lyon / Villejuif / Brussels / /
Company
Amgen Inc. / Genzyme / Trophogen Inc. / /
Country
Germany / Switzerland / Netherlands / Italy / Poland / Belgium / France / United States / Denmark / /
Event
FDA Phase / /
Facility
Larrey Hospital / Centre Leon Berard / Leiden University Medical Center / University of Pisa / Laboratory of Molecular Imaging / University of Siena / University of Pittsurgh / Alexander University / Memorial Cancer Center / Mayo Clinic / University of Texas M.D. Anderson Cancer Center / Cincinnati Children's Hospital / University of Texas M / Odense University Hospital / Albert Einstein College of Medicine / Claudius Regaud Institute / Institute of Oncology / University of Ferrara / /
University of Texas M.D. Anderson Cancer Center / Cancer Center / Leiden University / Cincinnati Children's Hospital / Memorial Cancer Center / Odense University / Federal Trade Commission / Universite Catholique de Louvain / Dana-Farber Cancer Institute / University of Pittsurgh / Odense University Hospital / Seattle Cancer Care Alliance / University of Pisa / Albert Einstein College of Medicine / FDA / University of Siena / Institute of Oncology / Nuclear Medicine and Endocrine Oncology / University of Texas / /
Person
Gustave Roussy / Leon Berard / /
Position
Head / /
Product
Thyrogen / Sherman1 / AMG / /
ProvinceOrState
Texas / Ohio / Minnesota / Maryland / New York / Washington / Pennsylvania / California / Massachusetts / /
Thyroid cancer Oral LONG-TERM OUTCOME IN 210 CASES OF PAPILLARY THYROID CARCINOMA (PTC) PRESENTING IN PATIENTS <21 YEARS OLD AND MANAGED AT ONE INSTITUTION DURING 1940–2005: A POSSIBLE PYRRHIC VICTORY? I. Hay1, T. Gonz